Earticle

초록

영어

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of insulin-producing beta-cells in the pancreas. Genetic variations within the major histocompatibility complex (MHC) significantly influence the development of T1D, with disease progression often indicated by the presence of autoantibodies. Until recently, insulin therapy was the sole treatment for T1D. However, in 2022, the Food and Drug Administration approved teplizumab, an anti-CD3 monoclonal antibody, as a novel immunomodulatory therapy to delay the onset of T1D. Various immunologic agents, including anti-CD antibodies and anti-cytokine autoantibodies, have been investigated across various stages of T1D in clinical trials. This article examines the current status of drug development for the prevention and treatment of T1D and summarizes key studies that aimed at delaying the onset of T1D using these agents. While efforts to halt or prevent the disease prior to clinical diagnosis have yielded limited success, post-diagnosis interventions have shown promising potential in slowing disease progression by preserving beta-cell function. Further investigation into long-term clinical outcomes related to the delay of T1D onset is necessary, and ongoing studies require extended follow-up to assess their full potential.

목차

ABSTRACT
1형당뇨병의 발병기전과 주요 약물표적
1형당뇨병의 진행과 예방
1차예방
2차예방
3차예방
항원요법
항CD 항체
사이토카인 억제제
기타
세포치료요법
결론 및 고찰
감사의 말씀
이해 상충
References

키워드

저자

• 손희석 [ Heeseok Sohn | 부산대학교 약학대학 ]
• 김수종 [ Sujong Kim | 부산대학교 약학대학 ]
• 윤정현 [ Jeong-Hyun Yoon | 부산대학교 약학대학, 부산대학교 신약개발연구소 ] Corresponding Author

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615